LONDON — A new non-invasive imaging agent has shown there can be unexpected changes in human epidermal growth factor receptor type 2 (HER2) status from primary breast cancer to metastatic disease, and that as a result some women are inappropriately being treated with HER2 positive-targeted drugs.

We've all heard about the FBI investigation into manufacturers of power morcellators, and much of the coverage comes across as breathlessness in search of a scandal. This story goes back to at least 2006 when Ethicon, the Johnson & Johnson subsidiary that withdrew its morcellators from the market last year, appended product labels to advise physicians of the potential for the spread of uterine neoplasms during morcellation for hysterectomy or fibroid removal. There are a number of moving parts to this saga, but the nagging question is still that of what prompted...